Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence

References

• GoldRWolinskyJSPathophysiology of multiple sclerosis and the place of teriflunomideActa Neurologica Scandinavica20111242758420880295
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdfAubagio, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• TallantyreEEvangelouNConstantinescuCSSpotlight on teriflunomideInternational MS Journal/MS Forum2008152626818782502
   PubMedGoogle Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisThe New England Journal of Medicine2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPComiGOral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology201413324725624461574
   PubMed Web of Science ®Google Scholar
• VermerschPCzlonkowskaAGrimaldiLMTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMultiple Sclerosis201420670571624126064
   PubMed Web of Science ®Google Scholar
• MillerAEWolinskyJSKapposLOral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology2014131097798625192851
   PubMed Web of Science ®Google Scholar
• FukushimaRKanamoriSHirashibaMTeratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in miceReproductive Toxicology2007243–431031617604599
   PubMed Web of Science ®Google Scholar
• KieseierBBenamorMPregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple SclerosisNeurology and Therapy20143133138
   PubMedGoogle Scholar
• Bar-OrAFreedmanMSKremenchutzkyMTeriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosisNeurology201381655255823851964
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnnals of Neurology201169229230221387374
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society NYMedications [webpage on the Internet]: Consensus on Disease-Modifying Therapies http://www.nationalmssociety.org/Treating-MS/Medications2014133Accessed 18.10.2014
   Google Scholar
• GoldRDiagnosis and treatment in multiple sclerosis. Guidelines of the German Society for Neurology (German)2014Accessed 26.12.2014
   Google Scholar
• HeesenCKleiterINguyenFRisk perception in natalizumab-treated multiple sclerosis patients and their neurologistsMultiple Sclerosis201016121507151220826527
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdfLemtrada, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdfAvonex, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdfRebif, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdfBetaferon, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000933/WC500034701.pdfExtavia, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002827/WC500170303.pdfPlegridy, Assessment reportAccessed 26.12.2014
   Google Scholar
• https://http://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdfCopaxone, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdfGilenya, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdfTysabri, Summary of Product CharacteristicsAccessed 26.12.2014
   Google Scholar
• CharlesCGafniAWhelanTShared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango)Social Science and Medicine19974456816929032835
   PubMed Web of Science ®Google Scholar
• RothwellPMMcDowellZWongCKDormanPJDoctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosisBMJ19973147094158015839169401
   PubMed Web of Science ®Google Scholar
• KopkeSKernSZiemssenTEvidence-based patient information programme in early multiple sclerosis: a randomised controlled trialJournal of Nneurology, Neurosurgery, and Psychiatry2014854411418
   PubMed Web of Science ®Google Scholar
• HansonKAAgashivalaNWyrwichKWRaimundoKKimEBrandesDWTreatment selection and experience in multiple sclerosis: survey of neurologistsPatient Preference and Adherence2014841542224729689
   PubMed Web of Science ®Google Scholar
• HeesenCKopkeSRichterTKasperJShared decision making and self-management in multiple sclerosis – a consequence of evidenceJournal of Neurology2007254Suppl 2II116II12117503119
   PubMedGoogle Scholar
• MendelRTraut-MattauschEFreyDDo physicians’ recommendations pull patients away from their preferred treatment options?Health Expectations: An International Journal of Public Participation in Health care and Health policy2012151233121323824
   PubMed Web of Science ®Google Scholar
• ProsserLAKuntzKMBar-OrAWeinsteinMCThe relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosisMedical Decision Making: An International Journal of the Society for Medical Decision Making200222650651312458981
   PubMed Web of Science ®Google Scholar
• VisserLHvan der ZandeAReasons patients give to use or not to use immunomodulating agents for multiple sclerosisEuropean Journal of Neurology: the Official Journal of the European Federation of Neurological Societies201118111343134921496180
   PubMed Web of Science ®Google Scholar
• WilsonLLoucksABuiCPatient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choicesJournal of the Neurological Sciences20143441–2808725037284
   PubMed Web of Science ®Google Scholar
• UtzKSHoogJWentrupAPatient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysisTherapeutic Advances in Neurological Disorders20147626327525371708
   PubMed Web of Science ®Google Scholar
• FoxEJVasquezAGraingerWGastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Multiple SclerosisMultiple Sclerosis Journal201420S1205
   Google Scholar
• LeistTPFreedmanSMKapposLPooled Safety Analyses From the Teriflunomide Clinical Development ProgramMultiple Sclerosis Journal201420S1110
   Google Scholar
• SabatéEAdherence to Long-Term Therapies: Evidence for ActionWorld Health OrganizationGeneva, Switzerland2003
   Google Scholar
• BrandesDWCallenderTLathiEO’LearySA review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse eventsCurrent Medical Research and Opinion2009251779219210141
   PubMed Web of Science ®Google Scholar
• ReynoldsMWStephenRSeamanCRajagopalanKPersistence and adherence to disease modifying drugs among patients with multiple sclerosisCurrent Medical Research and Opinion201026366367420070144
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJournal of Neurology2009256456857619444532
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJournal of Managed Care Pharmacy: JMCP2013191 Suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• UitdehaagBConstantinescuCCornelissePImpact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyTherapeutic Advances in Neurological Disorders20114131421339904
   PubMedGoogle Scholar
• Al-SabbaghABennetRKozmaCDicksonMMeleticheDMedication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJournal of Neurology2008255Suppl 2S79
   Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClinical Drug Investigation20103028910020067327
   PubMed Web of Science ®Google Scholar
• IvanovaJIBergmanREBirnbaumHGPhillipsALStewartMMeleticheDMImpact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the USJournal of Medical Economics201215360160922376190
   PubMedGoogle Scholar
• TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdvances in Therapy2011281516121153000
   PubMed Web of Science ®Google Scholar
• O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMultiple Sclerosis2005111465015732266
   PubMed Web of Science ®Google Scholar
• AgashivalaNWuNAbouzaidSCompliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort studyBMC Neurology20131313824093542
   PubMed Web of Science ®Google Scholar
• BergvallNPetrillaAAKarkareSUPersistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysisJournal of Medical Economics2014171069670725019581
   PubMedGoogle Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesThe American Journal of Managed Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClinical Therapeutics20012381296131011558866
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisThe New England Journal of Medicine2012367121098110722992073
   PubMed Web of Science ®Google Scholar